CNTG logo

Centogene NV (CNTG) Stock

Profile

Sector:

Healthcare

Country:

Germany

IPO:

07 November 2019

Indexes:

Not included

Description:

Centogene NV (CNTG) is a biotechnology company that focuses on genetic testing and rare disease research. They provide diagnostic solutions and data analysis to help identify genetic disorders, enabling better patient care and treatment options. Their work supports healthcare professionals in understanding complex genetic conditions.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Sept 06, 2024

Recent annual earnings:

Jan 18, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

28 June '23 HC Wainwright & Co.
Buy
18 May '23 HC Wainwright & Co.
Buy
27 Apr '23 HC Wainwright & Co.
Buy
13 Apr '23 HC Wainwright & Co.
Buy
12 Apr '23 HC Wainwright & Co.
Buy
22 Feb '23 HC Wainwright & Co.
Buy
17 Jan '23 HC Wainwright & Co.
Buy
23 Nov '22 HC Wainwright & Co.
Buy
18 July '22 SVB Leerink
Outperform
17 June '21 Credit Suisse
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
CNTG
globenewswire.com20 June 2024

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development for lysosomal diseases (LDs) and improve the quality of life for those impacted by these conditions.

Centogene shares climb after study confirms biomarker for Gaucher disease
Centogene shares climb after study confirms biomarker for Gaucher disease
Centogene shares climb after study confirms biomarker for Gaucher disease
CNTG
Market Watch01 September 2023

Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher disease, a rare inherited disorder that affects the body's ability to break down a certain type of fat. The study results also indicate that lyso-Gb1 could help predict the clinical course of patients and personalize care for the disease, Centogene said in a release.

CENTOGENE to Participate in Upcoming Conferences in May
CENTOGENE to Participate in Upcoming Conferences in May
CENTOGENE to Participate in Upcoming Conferences in May
CNTG
GlobeNewsWire05 May 2023

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced its conference schedule for May 2023. CENTOGENE representatives are attending events in Brazil, the U.S., and Germany, as well as virtually, and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities. The Company invites attendees to schedule one-on-one meetings in advance.

FAQ

  • What is the primary business of Centogene NV?
  • What is the ticker symbol for Centogene NV?
  • Does Centogene NV pay dividends?
  • What sector is Centogene NV in?
  • What industry is Centogene NV in?
  • What country is Centogene NV based in?
  • When did Centogene NV go public?
  • Is Centogene NV in the S&P 500?
  • Is Centogene NV in the NASDAQ 100?
  • Is Centogene NV in the Dow Jones?
  • When was Centogene NV's last earnings report?
  • When does Centogene NV report earnings?

What is the primary business of Centogene NV?

Centogene NV (CNTG) is a biotechnology company that focuses on genetic testing and rare disease research. They provide diagnostic solutions and data analysis to help identify genetic disorders, enabling better patient care and treatment options. Their work supports healthcare professionals in understanding complex genetic conditions.

What is the ticker symbol for Centogene NV?

The ticker symbol for Centogene NV is NASDAQ:CNTG

Does Centogene NV pay dividends?

No, Centogene NV does not pay dividends

What sector is Centogene NV in?

Centogene NV is in the Healthcare sector

What industry is Centogene NV in?

Centogene NV is in the Diagnostics & Research industry

What country is Centogene NV based in?

Centogene NV is headquartered in Germany

When did Centogene NV go public?

Centogene NV's initial public offering (IPO) was on 07 November 2019

Is Centogene NV in the S&P 500?

No, Centogene NV is not included in the S&P 500 index

Is Centogene NV in the NASDAQ 100?

No, Centogene NV is not included in the NASDAQ 100 index

Is Centogene NV in the Dow Jones?

No, Centogene NV is not included in the Dow Jones index

When was Centogene NV's last earnings report?

Centogene NV's most recent earnings report was on 6 September 2024

When does Centogene NV report earnings?

The date for Centogene NV's next earnings report has not been announced yet